"RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma Antagonists and Agonists"
Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but difficult-to-drug target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter.
The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concerns for novel RORgamma modulators were identified.
Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.
The report provides an understanding of:
- The target RORgamma
- Clinical and non-clinical target validation
- Clinical lead and up-side indications
- Drug discovery strategies and technologies
- Commercial value of drug discovery collaborations
- R&D timelines from start of screening to first-in-human studies
- Competitive landscape of RORgamma antagonists
- Agonists of RORgamma for cancer
- Profiles of unpartnered technology companies and lead projects
- R&D Partnerships and their discovery approaches and lead molecules
- Unpartnered pharmaceutical companies and their programs
Table of Contents
2) Executive Summary
3) Target Background
4) Target validation
5) Drug Discover Approaches & Technologies
6) Competitive Landscape of RORgamma Modulators
7) Corporate Stakeholders
Table 1: Disease Models Used for Non-Clinical Studies of RORgamma Antagonists
Table 2: Overview of Non-Clinical Studies of RORgamma Antagonists in Psoriasis Models
Table 3: Overview of Non-Clinical Studies of RORgamma Antagonists in Multiple Sclerosis Models
Table 4: Overview of Non-Clinical Studies of RORgamma Antagonists in Arthritis Models
Table 5: Overview of Non-Clinical Studies of RORgamma Antagonists in Inflammatory Bowel Disease and Ulcerative Colitis Models
Table 6: Overview of Non-Clinical Studies of RORgamma Antagonists in Systemic Lupus Erythematosus Models
Table 6: Overview of Partnership Agreements for RORgamma Modulators
Table 7: Special Collaborations for Discovery of RORgamma Antagonists
Table 8: Financial Terms of Partnership Agreements for RORgamma Modulators
Table 9: R&D Timeline for Discovery of RORgamma Antagonists in Partnership Programs
Table 10: Technologies for Discovery of RORgamma Antagonists
Table 11: RORgamma(T) Antagonists / Inverse Agonists in Clinical Development
Table 12: RORgamma(T) Antagonists / Inverse Agonists in pre-IND Studies
Table 13: RORgamma(T) Antagonists / Inverse Agonists in Preclinical R&D
Table 14: RORgamma(T) Antagonists / Inverse Agonists Discovery Programs
Table 15: RORgamma Agonists Discovery & Development Programs
Table 16: Technology and Pharma Companies with RORgamma Modulator R&D
Make an enquiry before buying this Report
Please fill the enquiry form below.
Lymphobalstic lymphoma is also known as non-hodgkin lymphoma a type of cancer that primarily affects lymphatic system. The lymphatic system comprises organs such as the thymus, bone marrow, spleen, and the lymph nodes (or lymph glands). Lymph nodes are connected by a network of tubes called lymphatic vessels that contain lymph fluid and lymphatic tissue is also found in other organs such as skin, lungs and stomach. Prevalence of lymphoblastic lym...
The global market for congestive heart failure treatment devices is expected to reach $5.9 billion by the year 2016 at the compounded annual growth rate of 11.7% during the forecasted period. This growth is mainly attributed by the rising incidences of heart failures across the world. American market for congestive heart failure treatment devices accounted for $1.6 billion in 2010 and is expected to reach $3.2 billion by the year 2016 at the CA...
Monoclonal antibodies have brought a paradigm shift in biotechnology and pharmaceutical sectors. Monoclonal antibodies (mAbs) are mono-specific antibodies which comprise of identical immune cells and these immune cells are clones of a single parent cell and are distinguished by their unique property to bind to the same epitope. Monoclonal antibodies are now used for treatment of a wide array of diseases, especially cancer, autoimmune, ...